
Novel Oncolytic Virus Based Cancer Therapy

ID# 2019-4999





Anti-tumor activity of Infectious Pancreatic Necrosis virus (OV1) and Infectious Bursal disease Virus (OV2) in a murine breast cancer model

Technology Summary

Members of the family Birnaviridae namely genus aquabirnavirus including Infectious Pancreatic Necrosis virus (IPNV) found in cold water fish, and genus avibirnavirus, including Infectious Bursal Disease virus (IBDV) found in poultry, are well-known and well-characterized viruses that are non-pathogenic to humans. IBDV and IPNV do not replicate productively within, or induce cell death of, non-cancerous human or mammalian cells.

Penn State inventors discovered that IBDV (or "OV1") and IPNV (or "OV2") can infect a range of human cancer cells, replicate, and induce apoptotic cell death. In vitro, OV1 and OV2 have demonstrated oncotoxicity, including activation of apoptosis, in a range of human cancers including human lung carcinoma, renal cell adenocarcinoma, pancreatic adenocarcinoma, mammary ductal carcinoma, and lymphoma. In addition, the double-stranded RNA genomes of IPNV and IBDV stimulate the immune system, so the immune cells attack and destroy cancer. Therefore, they serve as double-pronged attack on cancer.

Application & Market Utility

OV1 and OV2 have additionally demonstrated oncotoxicity in canine mammary carcinoma cells, suggesting that these oncolytic viruses will have therapeutic application in both companion animals and humans. The researchers have generated genetically modified OV1 and OV2 OV1 with enhanced oncotoxicity and carry therapeutic payload genes. Using a murine breast cancer model (4T1.2), the researchers demonstrated anti-tumor activities of OV1 and OV2.

Next Steps

Research is ongoing. Penn State researchers are working with collaborators to optimize the dose and delivery and the choice of therapeutic payloads to optimize anti-cancer efficacy of OV1 and OV2 in vivo in mouse models. Penn State seeks partners to advance treatment for indications in both human and animal health.

TECHNOLOGY READINESS LEVEL

3

Seeking

Licensing |

Keywords

- Oncolytic Virus
- Cancer Therapeutic
- Cancer

Researchers

PGCHE, FHEA, DipACVM, MBA
Interim Director of the Animal Diagnostic Laboratory
and Dorothy Foehr Huck and J. Lloyd Huck Chair in
Emerging Infectious Diseases
Website

Suresh V. Kuchipudi, BVSc, MVSc, PhD,

Other Researchers

Originating College

College of Agricultural Sciences

Office of Technology Management Contact

Long, Melissa mklong@psu.edu 814-865-5730



Invent Penn State is a Commonwealth-wide initiative to spur economic development, job creation, and student career success. Invent Penn State blends entrepreneurship-focused academic programs, business startup training and incubation, funding for commercialization, and university-community collaborations to facilitate the challenging process of turning research discoveries into valuable products and services that can benefit Pennsylvanians and humankind. Learn more at invent.psu.edu.

Penn State is an equal opportunity, affirmative action employer, and is committed to providing employment opportunities to all qualified applicants without regard to race, color, religion, age, sex, sexual orientation, gender identity, national origin, disability or protected veteran status.